ARVN - Arvinas Inc.

-

$undefined

N/A

(N/A)

Arvinas Inc. NasdaqGS:ARVN Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Location: 5 Science Park, New Haven, CT, 06511, United States | Website: https://www.arvinas.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-396.4M

Cash

954.3M

Avg Qtr Burn

-62.68M

Short % of Float

12.12%

Insider Ownership

6.75%

Institutional Own.

86.58%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Vepdegestrant (ARV-471) + Palbociclib Details
Breast cancer, Cancer, Solid tumor/s

Phase 3

Data readout

Vepdegestrant (Mono) Details
Solid tumor/s, Cancer, Breast cancer

Susp. Mover™

Phase 3

Data readout

Vepdegestrant + Atirmociclib (1L) Details
Solid tumor/s, Cancer, Breast cancer

Phase 3

Initiation

Vepdegestrant (ARV-471) Details
Cancer, Breast cancer, Solid tumor/s

Phase 2

Data readout

ARV-766 +/- Abiraterone Details
Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer

Phase 1/2

Update

Vepdegestrant (ARV-471)+CDK4 inhibitor Details
Solid tumor/s, Cancer, Breast cancer

Phase 1/2

Update

Phase 1/2

Update

Bavdegalutamide (ARV-110) +/- Aabiraterone Details
Prostate cancer, Cancer, Castration-resistant prostate cancer, Solid tumor/s

Phase 1/2

Update

Vepdegestrant (ARV-471) Details
Cancer, Breast cancer, Solid tumor/s

Phase 1

Data readout

ARV-393 Details
Cancer, B-cell lymphoma, Blood cancer

Phase 1

Data readout

ARV-102 Details
Neurodegenerative disease, Parkinson's disease

Phase 1

Data readout